Drugs / MISETIONAMIDE
MISETIONAMIDE
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03854110 | Jan 2019 → Jun 2026 overdue | malignant pancreatic neoplasm | Geistlich Pharma AG | Active not recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MISETIONAMIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314425 ↗ |
| Known as | GP-2250 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03854110 ↗ |
| Known as | Misetionamida | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314425 ↗ |
| Modality | Small molecule | — CHEMBL5314425 ↗ |
| Route | Intravenous | “doses of 250 mg up to 30 grams intravenously” NCT03854110 ↗ |